youtube_live
Q3 2026 earnings • released • EPS beat +1.09% • Revenue beat +0.35%
See resultschevron_right
ABBV:NYSE
AbbVie Common Stock
$288.84
arrow_downward
-2.05%(-6.05) 1D
$289.74
arrow_upward
+0.31% (+0.90)bedtimeAfter hours
Closed: Nov 2, 4:03:02 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABBV...
Open
$290.38
High
$294.86
Low
$286.14
Mkt. cap
510.41B
Avg. vol.
4.80M
Volume
8.85M
Dividend
2.52%
Quarterly dividend
$1.82
Ex-dividend date
Oct 15, 2026
P/E ratio
81.69
52-wk high
$298.74
52-wk low
$190.75
EPS
$3.54
Beta
0.23
Shares outstanding
1.77B
No. of employees
57K
Open
$290.38
High
$294.86
Low
$286.14
Mkt. cap
510.41B
Avg. vol.
4.80M
Volume
8.85M
Dividend
2.52%
Quarterly dividend
$1.82
Ex-dividend date
Oct 15, 2026
P/E ratio
81.69
52-wk high
$298.74
52-wk low
$190.75
EPS
$3.54
Beta
0.23
Shares outstanding
1.77B
No. of employees
57K
News stories
From web sources and news partners
Yahoo Finance
·
1 hour ago
ABBV 8-K & SEC Filings
GuruFocus
·
8 hours ago
ABBV Maintains Outperform Rating -- Price Target Raised to $342
Benzinga
·
13 hours ago
AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate
Benzinga
·
13 hours ago
Growth And Cyclical Sectors Lead Monday Trading
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57K
FoundedApr 10, 2012
HeadquartersNorth Chicago, Illinois, United States
SectorBiotechnology
Websiteabbvie.com
Analyst ratings
Based on 24 analysts giving stock ratings to ABBV in the past 3 months
Strong buy
Buy
20
Hold
4
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current $288.84
$346.00 (+19.79%)
Average
$306.23 (+6.02%)
Lowest
$230.00 (-20.37%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
David Risinger Leerink Partners | Buy | Reiterated | $325.00 | +12.5% | 11/02/2026 |
Carter Gould Cantor Fitzgerald | Buy | Maintained | $325.00 | +12.5% | 11/02/2026 |
Vamil Divan Guggenheim | Buy | Reiterated | $322.00 | +11.5% | 11/01/2026 |
Gary Nachman Canaccord Genuity | Buy | Reiterated | $338.00 | +17% | 11/02/2026 |
Geoff Meacham Citi | Hold | Maintained | $295.00 | +2.1% | 11/02/2026 |
Terence Flynn Morgan Stanley | Buy | Reiterated | $346.00 | +19.8% | 11/02/2026 |
Michael Yee UBS | Hold | Reiterated | $295.00 | +2.1% | 11/02/2026 |
Asad Haider Goldman Sachs | Hold | Maintained | $294.00 | +1.8% | 10/30/2026 |
Mohit Bansal Wells Fargo | Buy | Maintained | $340.00 | +17.7% | 10/30/2026 |
Jason Gerberry Bank of America Securities | Buy | Reiterated | $319.00 | +10.4% | 10/30/2026 |
Trung Huynh RBC Capital | Buy | Reiterated | $330.00 | +14.3% | 10/30/2026 |
Louise Chen Scotiabank | Buy | Maintained | $320.00 | +10.8% | 10/29/2026 |
David Amsellem Piper Sandler | Buy | Maintained | $303.00 | +4.9% | 10/26/2026 |
Courtney Breen Bernstein | Hold | Maintained | $230.00 | -20.4% | 10/25/2026 |
Emily Field Barclays | Buy | Maintained | $325.00 | +12.5% | 10/21/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $300.00 | +3.9% | 10/12/2026 |
Chris Schott J.P. Morgan | Buy | Reiterated | $300.00 | +3.9% | 10/08/2026 |
Tim Anderson Bank of America Securities | Buy | Reiterated | $289.00 | +0.1% | 09/29/2026 |
Matt Phipps William Blair | Buy | Maintained | - | - | 09/28/2026 |
Steve Scala TD Cowen | Buy | Maintained | $280.00 | -3.1% | 09/28/2026 |
Luisa Hector Berenberg Bank | Buy | Reiterated | $275.00 | -4.8% | 09/10/2026 |
Rajesh Kumar HSBC | Buy | Maintained | $315.00 | +9.1% | 09/10/2026 |
William Katz TD Cowen | Buy | Reiterated | $280.00 | -3.1% | 09/04/2026 |
Alexandria Hammond Wolfe Research | Buy | Upgraded | $300.00 | +3.9% | 08/13/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Reiterated | $260.00 | -10% | 08/10/2026 |
Hans Engel Erste Group | Buy | Upgraded | - | - | 08/05/2026 |
Michael Harvey RBC Capital | Buy | Reiterated | $280.00 | -3.1% | 07/10/2026 |
Tyler Van Buren TD Cowen | Buy | Reiterated | $280.00 | -3.1% | 06/23/2026 |
Nicholas Lorusso TD Cowen | Buy | Reiterated | $280.00 | -3.1% | 06/23/2026 |
Jasper Hellweg Argus Research | Buy | Reiterated | $250.00 | -13.4% | 05/13/2026 |
Unknown Analyst Canaccord Genuity | Buy | Initiated | $262.00 | -9.3% | 04/20/2026 |
Nico Chen DBS | Hold | Maintained | $230.00 | -20.4% | 02/25/2026 |
Last report
Oct 30, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$3.82 / $3.78
+1.09%beat
arrow_upward
Revenue / Est. (USD)
17.40B / 17.34B
+0.35%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 16.62B | 15.00B | 16.99B | 17.40B |
Cost of goods sold | 4.55B | 4.22B | 4.29B | 4.28B |
Cost of revenue | 4.55B | 4.22B | 4.29B | 4.28B |
Research and development expenses | 2.58B | 2.47B | 2.34B | 2.42B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.82B | 3.49B | 3.55B | 3.84B |
Operating expense | 6.40B | 5.96B | 5.90B | 6.24B |
Total operating expenses | 10.95B | 10.18B | 10.19B | 10.52B |
Operating income | 5.67B | 4.82B | 6.80B | 6.88B |
Other non operating income | 120.00M | -3.00M | -55.00M | 91.00M |
EBT including unusual items | 2.67B | 1.04B | 4.28B | 4.83B |
EBT excluding unusual items | 5.12B | 4.19B | 6.07B | 6.28B |
Income tax expense | 853.00M | 342.00M | 662.00M | 609.00M |
Effective tax rate | 31.97% | 32.92% | 15.47% | 12.61% |
Other operating expenses | - | - | - | -18.00M |
Net income | 1.82B | 695.00M | 3.61B | 4.22B |
Net profit margin | 10.93% | 4.63% | 21.27% | 24.24% |
Earnings per share | 2.71 | 2.65 | 3.65 | 3.82 |
Interest and investment income | 59.00M | 72.00M | 67.00M | - |
Interest expense | -714.00M | -717.00M | -746.00M | -688.00M |
Net interest expenses | -655.00M | -645.00M | -679.00M | -688.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 7.66B | 6.76B | 8.68B | 8.76B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events